Jonathan A. Ledermann
乔纳森·莱德曼
MD, FRCP
Emeritus Professor of Medical Oncology; Honorary Consultant Medical Oncologist医学肿瘤学荣誉教授；荣誉顾问医学肿瘤学家
👥Biography 个人简介
Jonathan A. Ledermann, MD, FRCP is an internationally recognized oncologist and Emeritus Professor at University College London, best known for leading the STUDY-19 trial that provided the first clinical evidence of olaparib's efficacy as maintenance therapy in BRCA-mutated ovarian cancer. His foundational work contributed directly to the regulatory approval of olaparib (Lynparza) and transformed the treatment paradigm for relapsed high-grade serous ovarian cancer. Professor Ledermann has served in senior leadership roles at the European Organisation for Research and Treatment of Cancer (EORTC) and Cancer Research UK.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Olaparib Maintenance — STUDY-19
Led the phase II STUDY-19 trial that first demonstrated clinically meaningful progression-free survival benefit of olaparib maintenance in platinum-sensitive relapsed ovarian cancer, particularly in BRCA mutation carriers, establishing the proof-of-concept for PARP inhibitor maintenance.
BRCA Biomarker Validation
Conducted landmark biomarker analyses confirming BRCA1/2 mutation status as a predictive biomarker for olaparib benefit, directly informing the FDA and EMA approval label for olaparib.
EORTC Gynecologic Cancer Leadership
Directed and co-directed multiple EORTC gynecologic cancer group trials, shaping European clinical trial standards in ovarian and endometrial cancer.
Representative Works 代表性著作
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
New England Journal of Medicine (2012)
Phase II trial establishing olaparib as maintenance therapy in relapsed ovarian cancer, the foundational study for PARP inhibitor maintenance.
Olaparib Maintenance in Patients with Platinum-Sensitive Relapsed Serous Ovarian Cancer: a Preplanned Retrospective Analysis of Outcomes by BRCA Status
The Lancet Oncology (2014)
Biomarker analysis confirming profound PFS benefit of olaparib in BRCA-mutated patients.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 乔纳森·莱德曼 的研究动态
Follow Jonathan A. Ledermann's research updates
留下邮箱，当我们发布与 Jonathan A. Ledermann（University College London Cancer Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment